9SZM | pdb_00009szm

Human fumarylacetoacetate hydrolase (FAH) in complex with 3C10

External Resource: Annotation

Domain Annotation: ECOD Classification
Protein Family Annotation
Gene Ontology: Gene Product Annotation
InterPro: Protein Family Classification
Pharos: Disease Associations

Domain Annotation: ECOD Classification ECOD Database Homepage

Chains	Family Name	Domain Identifier	Architecture	Possible Homology	Homology	Topology	Family	Provenance Source (Version)
B [auth A]	ClpB_D2-small	e9szmA1	A: alpha arrays	X: Hypothetical protein YqbG-like	H: Hypothetical protein YqbG-like	T: alpha/beta-Hydrolases	F: ClpB_D2-small	ECOD (v295.2)
A [auth B]	ClpB_D2-small	e9szmB1	A: alpha arrays	X: Hypothetical protein YqbG-like	H: Hypothetical protein YqbG-like	T: alpha/beta-Hydrolases	F: ClpB_D2-small	ECOD (v295.2)

Protein Family Annotation Pfam Database Homepage

Chains	Accession	Name	Description	Comments	Source
A [auth B], B [auth A]	PF01557	Fumarylacetoacetate (FAA) hydrolase C-terminal (FAA_hydrolase)	Fumarylacetoacetate (FAA) hydrolase C-terminal	This entry consists of fumarylacetoacetate (FAA) hydrolase, or fumarylacetoacetate hydrolase (FAH) and it also includes HHDD isomerase/OPET decarboxylase from E. coli strain W. FAA is the last enzyme in the tyrosine catabolic pathway, it hydrolyses f ...	This entry consists of fumarylacetoacetate (FAA) hydrolase, or fumarylacetoacetate hydrolase (FAH) and it also includes HHDD isomerase/OPET decarboxylase from E. coli strain W. FAA is the last enzyme in the tyrosine catabolic pathway, it hydrolyses fumarylacetoacetate into fumarate and acetoacetate which then join the citric acid cycle [1]. Mutations in FAA cause type I tyrosinemia in humans this is an inherited disorder mainly affecting the liver leading to liver cirrhosis, hepatocellular carcinoma, renal tubular damages and neurologic crises amongst other symptoms [1]. The enzymatic defect causes the toxic accumulation of phenylalanine/tyrosine catabolites [3]. The E. coli W enzyme HHDD isomerase/OPET decarboxylase contains two copies of this domain and functions in fourth and fifth steps of the homoprotocatechuate pathway; here it decarboxylates OPET to HHDD and isomerises this to OHED. The final products of this pathway are pyruvic acid and succinic semialdehyde. This family also includes various hydratases and 4-oxalocrotonate decarboxylases which are involved in the bacterial meta-cleavage pathways for degradation of aromatic compounds. 2-hydroxypentadienoic acid hydratase encoded by mhpD in E. coli Swiss:P77608 is involved in the phenylpropionic acid pathway of E. coli and catalyses the conversion of 2-hydroxy pentadienoate to 4-hydroxy-2-keto-pentanoate and uses a Mn2+ co-factor [5]. OHED hydratase encoded by hpcG in E. coli Swiss:P42270 is involved in the homoprotocatechuic acid (HPC) catabolism [6]. XylI in P. putida Swiss:P49155 is a 4-Oxalocrotonate decarboxylase [7]. This entry also includes Oxaloacetate tautomerases that converts enol-oxaloacetate, a strong inhibitor of succinate dehydrogenase to the keto form of oxaloacetate [8].	Domain
A [auth B], B [auth A]	PF09298	Fumarylacetoacetase N-terminal (FAA_hydrolase_N)	Fumarylacetoacetase N-terminal	The N-terminal domain of fumarylacetoacetate hydrolase is functionally uncharacterised, and adopts a structure consisting of an SH3-like barrel [1].	Domain

Gene Ontology: Gene Product Annotation Gene Ontology Database Homepage

Chains	Polymer	Molecular Function	Biological Process	Cellular Component
A [auth B], B [auth A]	Fumarylacetoacetase	hydrolase activity, acting on carbon-carbon bonds hydrolase activity, acting on carbon-carbon bonds, in ketonic substances fumarylacetoacetase activity hydrolase activity catalytic activity	aromatic amino acid catabolic process catabolic process L-phenylalanine catabolic process aromatic amino acid metabolic process oxoacid metabolic process carboxylic acid metabolic process amino acid metabolic process primary metabolic process proteinogenic amino acid metabolic process proteinogenic amino acid catabolic process carboxylic acid catabolic process metabolic process cellular process small molecule metabolic process aromatic amino acid catabolic process catabolic process L-phenylalanine catabolic process aromatic amino acid metabolic process oxoacid metabolic process carboxylic acid metabolic process amino acid metabolic process primary metabolic process proteinogenic amino acid metabolic process proteinogenic amino acid catabolic process carboxylic acid catabolic process metabolic process cellular process small molecule metabolic process small molecule catabolic process amino acid catabolic process L-tyrosine catabolic process	cellular anatomical structure intracellular anatomical structure cytoplasm cytosol extracellular exosome membrane-bounded organelle extracellular vesicle extracellular organelle extracellular region organelle vesicle extracellular membrane-bounded organelle

InterPro: Protein Family Classification InterPro Database Homepage

Chains	Accession	Name	Type
A [auth B], B [auth A]	IPR036663	Fumarylacetoacetase-like, C-terminal domain superfamily	Homologous Superfamily
A [auth B], B [auth A]	IPR036462	Fumarylacetoacetase, N-terminal domain superfamily	Homologous Superfamily
A [auth B], B [auth A]	IPR005959	Fumarylacetoacetase	Family
A [auth B], B [auth A]	IPR011234	Fumarylacetoacetase-like, C-terminal	Domain
A [auth B], B [auth A]	IPR015377	Fumarylacetoacetase, N-terminal	Domain

Pharos: Disease Associations Pharos Homepage Annotation

Chains	Drug Target	Associated Disease
A [auth B], B [auth A]	: P16930	tyrosinemia tyrosinemia type I tyrosinemia type III breast cancer ductal breast carcinoma in situ invasive ductal breast carcinoma malignant mesothelioma ovarian cancer renal tubular acidosis cholestasis inborn errors of metabolism large cell medulloblastoma medulloblastoma pancreatic ductal adenocarcinoma subependymal giant cell astrocytoma tyrosinemia tyrosinemia type I tyrosinemia type III breast cancer ductal breast carcinoma in situ invasive ductal breast carcinoma malignant mesothelioma ovarian cancer renal tubular acidosis cholestasis inborn errors of metabolism large cell medulloblastoma medulloblastoma pancreatic ductal adenocarcinoma subependymal giant cell astrocytoma Cholestasis in newborn intellectual disability malignant ependymoma osteosarcoma psoriasis